1 / 4

Can denovoSkin Be A Lifesaver for Burn Victims

Burn is a global public health problem, affecting more than 180,000 deaths each year around the world. Most of these take place in low- and middle-income countries. Moreover, non-fatal burns are a significant source of morbidity, resulting in lengthy hospitalisation, disfigurement, and disability, as well as stigma and rejection.

xmichael
Download Presentation

Can denovoSkin Be A Lifesaver for Burn Victims

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Can denovoSkin Be A Lifesaver for Burn Victims? Burn is a global public health problem, affecting more than 180,000 deaths each year around the world. Most of these take place in low- and middle-income countries. Moreover, non-fatal burns are a significant source of morbidity, resulting in lengthy hospitalisation, disfigurement, and disability, as well as stigma and rejection. According to DelveInsight's data, there are a lot of burn victims in the seven major nations of the US, the EU-5 (Germany, France, Italy, Spain, and the UK), and Japan. In the US alone, there were around 459K burn victims who needed treatment in 2021; this number is anticipated to rise by 2032 at a significant CAGR over the projected period of 11 years (2022-2032). Burn burns are frequently disregarded injuries that result in high morbidity and mortality. Multiple organ failures may result from the difficult-to-manage immunological and inflammatory response, metabolic alterations, and distributive shock that are all linked to severe burns. It is necessary to address the significant long-term changes they bring about to improve the quality of life. These wounds are typically categorised according to their seriousness, depth, and size. Re-epithelialization is frequently challenging in cases with severe burns. Skin autografting is utilised to treat severe cases of burn patients who have lost their dermis and have a

  2. full-thickness defect and cannot be treated by surgeons. This is done using full-thickness skin grafts (FTSGs) or split-thickness skin grafts (STSGs). These grafts, which are taken from the patients themselves, have serious drawbacks. First, it is impossible to discover a match for allotransplantation in emergency situations since there is no location from which grafts may be taken in acute cases of burns. Second, the excised locations leave permanent scars. The Advanced Therapy Medicinal Product (ATMP), denovoSkin, is being developed by CUTISS AG, a Swiss company specialising in regenerative skin medicine and tissue engineering. It contains cells that were isolated from a stamp-sized patient split-thickness biopsy and cultured over a collagen hydrogel. The availability of grafts in the burns market has always been plagued by significant issues with the re-harvesting and meshing of STSG. Insufficient permanent skin coverage, a significant concern in cases of severe burn injuries, is addressed with denovoSkin, a dermo-epidermal skin graft. The dermal compartment and the well-stratified epidermis were investigated over a three-month period in Phase I burns clinical trials. Currently, biologics, standard burn care products, improved dressings, and other treatments predominate in treating burns. Alginate dressings, hydrogel dressings, foam dressings, hydrocolloid dressings, collagen dressings, and others are examples of advanced dressings. The use of biologics, such as skin grafts and other conventional burn care items, is also common. Burn rehabilitation and treatments are highly pricey, and many unmet needs remain. The original production of CUTISS's products occurred at the Wyss Zurich Regenerative Medicine Technologies Platform's GMP facility at the University of Zurich. However, it has now moved its regenerative medicine technology from Wyss Zurich to CUTISS, making it one of the first businesses to attain complete independence in its production capabilities with an onsite facility. DenovoSkin has been given an Orphan Drug Designation for treating burns by Swissmedic, EMA, and FDA. The Swiss engineering firms that have contributed most to the development of this medication are Zühlke Engineering and CSEM. These recognitions will assist denovoSkin in becoming the first-in-class automated tissue therapy that can effectively, safely, and conveniently treat both adults and children. This technology may also be used for other elective/reconstructive indications, such as tumour resections, plastic surgery, etc. It promises to advance skin surgery and transform the way burns are now treated. Related Reports: Diagnostic Imaging Equipment Market Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a

  3. steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases. Invasive Candidiasis Market "DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW. Sialidosis Market DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Filgrastim Biosimilar Insight DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Pain Management Devices Market Pain Management Devices Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 Latest Reports by DelveInsight Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market | Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis

  4. Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market To know more about our Competitive Services, Click here: Pharma Competitive Intelligence https://www.delveinsight.com/consulting/competitive-intelligence-services

More Related